PLSE241220P32000
- 0.00
- 0.000.00%
Pulse Biosciences Newsroom
Insider Purchase: Director at $PLSE (PLSE) Buys 50,000 Shares
Pulse Biosciences CEO Resigns Amid Leadership Transition
Express News | Pulse Biosciences Inc - CEO Burke T. Barrett to Resign Effective December 6, 2024
Sector Update: Health Care Stocks Higher Late Afternoon
Sector Update: Health Care
Pulse Biosciences Stock Rises; Co-Chairman Duggan May Buy Shares
Pulse Biosciences, Inc.'s (NASDAQ:PLSE) Largest Shareholder, Top Key Executive Robert Duggan Sees Holdings Value Fall by 4.8% Following Recent Drop
12 Health Care Stocks Moving In Friday's Intraday Session
Pulse Biosciences New Treatment Study Shows Reduction of Benign Thyroid Nodules
Pulse Biosciences Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in Q3 EPS Results.
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
Q3 2024 Pulse Biosciences Inc Earnings Call
Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript Summary
Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript
Pulse Biosciences | 10-Q: Q3 2024 Earnings Report
Express News | Pulse Biosciences Q3 Income From Operations USD -13.655 Million
Pulse Biosciences 3Q Loss $12.7M >PLSE
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
Express News | Pulse Biosciences Announces Appointment of David Kenigsberg, M.d. as Chief Medical Officer of Electrophysiology
Pulse Biosciences (PLSE.US) will release its financial report after the market closes on October 30th.
$Pulse Biosciences (PLSE.US)$ will release its financial report after the market closes on October 30. How was its previous performance? In 2024 Q2, revenue was $0.0, net income was -$-11.383 million, and EPS was -$0.2. In 2023 Q3, revenue was $0.0, net income was -$-10.566 million, and EPS was -$0.186832. The above data is based on US GAAP accounting standards. Reminder from Futubull.